Centrient appoints Onno Krap as Chief Financial Officer
Rotterdam, October 21 - Centrient, a global leader in sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals, today announced the appointment of Onno Krap as Chief Financial Officer, effective immediately. Onno Krap succeeds Ronald Merckx, who is stepping down after seven years with the company.
Onno Krap brings more than 30 years of international finance and business leadership experience across life sciences, healthcare, technology, software, and manufacturing. He has held CFO and senior finance leadership positions at organisations including Alfen, Exact, Kinly, Crucell, and Applied Biosystems.
Faye Freeman, Chief Executive Officer, commented: “I would like to thank Ronald for his commitment to Centrient and the important contribution he has made over the past seven years. Under his leadership, the finance organisation has played a key role in supporting the company through a period of significant change and development.
I am delighted to welcome Onno to Centrient. He brings a wealth of experience, a collaborative leadership style, and a strong track record of building high performing teams and leading organisations through periods of change. I am confident he will be a valuable addition to our Executive Leadership Team as we continue to strengthen our business and deliver on our ambitions for the future.”
Commenting on his appointment, Onno Krap said: “I am excited to be joining Centrient at such an important time in its journey. The company’s purpose, its commitment to customers, and the important role it plays in global healthcare strongly resonate with me. I look forward to working with colleagues across the organisation as we build on Centrient’s strong foundations and shape the next chapter together.”
________________________________________________________
About Centrient Pharmaceuticals
Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals. We are a pharmaceutical company with a clear Purpose: to improve lives through innovative and sustainable manufacturing of medicines - saving the lives of millions of people around the world annually. Regarding our portfolio, we produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as finished dosage forms (FDFs). Centrient Pharmaceuticals is a Board Member of the AMR Industry Alliance and a long-time advocate for industry responsibility in manufacturing.
For more information, please visit www.centrient.com, www.linkedin.com/company/centrient or contact us at info@centrient.com.
“Centrient Pharmaceuticals”, “Centrient” in this content are sometimes used for convenience where references are made to Centrient International Pharmaceuticals B.V, and or one or more of its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Centrient Pharmaceuticals International B.V. and or one or more of its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. “Subsidiaries”, “Centrient subsidiaries” and “Centrient companies” as used in this content refer to entities over which Centrient Pharmaceuticals International B.V. either directly or indirectly has control. The term “Centrient interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Centrient Pharmaceuticals International B.V. in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.
